International Scholarly Research Notices / 2015 / Article / Tab 2

Research Article

Assessment of Tachykinin Receptor 3′ Gene Polymorphism rs3733631 in Rosacea

Table 2

Distribution of genotypes among patients with rosacea and healthy controls.

ControlsPatientsOR95% CI value

Total
 Genotype
  C/C106 (87.7)108 (84.4)Ref.
  C/G14 (11.6)17 (13.3)1.210.57–2.580.621
  G/G1 (0.8)3 (2.3)3.160.32–31.070.325
 Recessive model
  C/C106 (87.7)108 (84.4)Ref.
  C/G or G/G15 (12.4)20 (15.6)1.340.65–2.760.433
 Allele contrast
  C226 (93.4)233 (91.0)Ref.
  G16 (6.6)23 (9.0)1.430.73–2.780.295

Males
 Genotype
  C/C47 (87.0)41 (77.3)Ref.
  C/G7 (13.0)9 (17.0)1.480.50–4.340.478
  G/G0 (0.0)3 (5.7)
 Recessive model
  C/C47 (87.0)41 (77.3)Ref.
  C/G or G/G7 (13.0)12 (22.7)1.970.71–1.020.193
 Allele contrast
  C101 (93.5)91 (85.8)Ref.
  G7 (6.5)15 (14.2)2.380.93–6.110.071

Females
 Genotype
  C/C59 (88.1)67 (89.3)Ref.
  C/G7 (10.4)8 (10.7)1.020.35–2.990.973
  G/G1 (1.5)0 (0.0)
 Recessive model
  C/C59 (88.1)67 (89.3)Ref.
  C/G or G/G8 (11.9)8 (10.7)0.90.32–2.540.835
 Allele contrast
  C125 (93.3)142 (94.7)Ref.
  G9 (6.7)8 (5.3)0.80.30–2.130.65

Note: statistical significance for differences in genotype, G-containing genotype, and allelic frequencies between patients with rosacea and healthy controls: (i)   = 1.113, df = 2, and = 0.573; = 0.537, df = 1, and = 0.464; = 0.970, df = 1, and = 0.325 among the entire cohort; (ii) = 3.650, df = 1, and = 0.161; = 1.716, df = 1, and = 0.190; = 3.412, df = 1, and = 0.065 among males; (iii) = 1.127, df = 1, and = 0.569; = 0.057, df = 1, and = 0.811; = 0.241, df = 1, and = 0.624 among females. Data are number of subjects and percentage (%); adjusted for age and gender.